Therapeutic drug monitoring: A way to improve long-term immunological balance?

摘要

During the last few decades allogeneic hematopoietic stem cell transplant (HSCT) has evolved as a curative treatment for several malignant and non-malignant hematological and immunological disorders. However, its use is associated with life-threatening complications including infections, malignancies, graft-versus-host disease (GVHD) and relapse of the underlying disorder [1].